India, July 1 -- Can-Fite BioPharma Ltd. (CANF) reported that its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma met its primary safety endpoint and demonstrated encouraging survival outcomes.
The open-label trial enrolled 20 patients who had progressed after standard therapies. Fourteen received Namodenoson as third-line treatment, five as second-line treatment, and one as fourth line. The drug was well tolerated, consistent with prior studies. Among evaluable third-line patients, median overall survival exceeded five months, with 62.5% surviving at least five months and 37.5% surviving seven months or longer. Two patients remained alive at data cutoff, including one continuing treatment. Notably, a second-line...